Citius to highlight corporate strategy and key pipeline assets Mino-Lok® and NC i-MSC
PR Newswire
CRANFORD, N.J.
,
May 11, 2021
/PRNewswire/ — Citius Pharmaceuticals, Inc. (“Citius” or the “Company”) (Nasdaq: CTXR) today announced that it will participate in a fireside chat at the Gabelli Funds Virtual Microcap Symposium.
Event Details:
Date: May 18, 2021
Time: 10:30am ET
Investors may register for the conference at the
event website
.
Citius President and Chief Executive Officer
Myron Holubiak
will focus on the execution of corporate strategy and capital deployment as the Company advances key pipeline assets including Mino-Lok®, a late-stage antibiotic lock solution for the treatment of patients with catheter-related bloodstream infections (CRBSIs), and NC
i
-MSC, a novel stem cell therapy for the treatment of Acute Respiratory Distress Syndrome (ARDS), a life-threatening condition, and the most common cause of respiratory failure and death in COVID-19 patients. Currently, there is no FDA-approved drug therapy available for ARDS.
About Citius Pharmaceuticals, Inc.
Citius is a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on anti-infectives in adjunct cancer care, unique prescription products, and stem cell therapy. The Company’s lead product candidate, Mino-Lok®, an antibiotic lock solution for the treatment of patients with catheter-related bloodstream infections (CRBSIs), is currently enrolling patients in a Phase 3 pivotal superiority trial. Mino-Lok® was granted Fast Track designation by the U.S. Food and Drug Administration (FDA). Through its subsidiary, NoveCite, Inc., Citius is developing a novel proprietary stem cell treatment derived from induced pluripotent stem cells (iPSCs) for acute respiratory conditions, with a near-term focus on Acute Respiratory Distress Syndrome (ARDS) associated with COVID-19. For more information, please visit
www.citiuspharma.com
.
Investor Relations for Citius Pharmaceuticals:
Andrew Scott
Vice President, Special Projects
T: 908-967-6677 x105
E:
[email protected]
Ilanit Allen
T: 908-967-6677 x113
E:
[email protected]
View original content:
http://www.prnewswire.com/news-releases/citius-pharmaceuticals-to-participate-in-fireside-chat-at-the-gabelli-funds-virtual-microcap-symposium-on-tuesday-may-18-301289094.html
SOURCE Citius Pharmaceuticals, Inc.
